CIBUS INC Stock Price, News & Analysis

Cibus (NASDAQ: CBUS) has issued a significant correction regarding previously reported rice gene editing conversion rates. The company acknowledged that the previously announced rates of 10-25% in Rice have not been reconfirmed, citing high variability in conversion rate data from subsequent experiments.

Despite this setback, Cibus continues to advance its oligonucleotide directed mutagenesis (ODM) editing technologies to improve editing conversion rates across various crops. The company maintains confidence in its Rapid Trait Development System™ (RTDS®) to meet customer requirements for trait editing in their germplasm through a time-bound and predictable process.

Cibus (Nasdaq: CBUS), a leading agricultural biotechnology company specializing in proprietary gene editing technologies for seed trait development, has announced its participation in the upcoming Sidoti Micro Cap Conference. The company's presentation will be delivered by Co-Founders Rory Riggs (CEO and Chairman) and Peter Beetham (President and COO) on Thursday, January 23, 2025, at 1:45 p.m. ET (10:45 a.m. PT). The presentation will be accessible via webcast to registered participants.

Cibus Inc (NASDAQ: CBUS) has announced a $22.6 million registered direct offering of 9,040,000 shares of Class A Common Stock, including pre-funded warrants, priced at $2.50 per share. The offering includes warrants to purchase an additional 9,040,000 shares, exercisable at $2.50 per share upon stockholder approval, with a five-year expiration term.

The company will use the proceeds to fund development of productivity traits pipeline and working capital. The offering, expected to close around January 24, 2025, involves existing investors, including CEO Rory Riggs. Additionally, Cibus is amending terms for existing warrant holders, reducing exercise price from $10.00 to $2.50 per share and extending the termination date to five years post-offering.

Cibus (NASDAQ: CBUS) has announced significant breakthroughs in its proprietary RTDS gene editing process, establishing production standards that enable trait development in customer's elite germplasm within 12 months. The company has achieved standardization for traits in Rice (herbicide tolerance HT1 and HT3) and Canola (pod shatter reduction, herbicide tolerance HT2, and Sclerotinia resistance).

Key advances include improved cell biology technology, enhanced oligonucleotide directed mutagenesis (ODM) editing platform with conversion rates of 10-25% in Rice and up to 50% in Canola, and streamlined semi-automated regeneration processes. While missing its 2024 goal for an operational soybean platform, Cibus successfully edited Soybean cells with HT2 trait genetic changes.

The company's standardized process represents a significant shift from conventional breeding methods, offering a timebound and predictable system for trait development. These genetic changes are expected to be regulated similarly to naturally occurring traits, distinguishing them from GMOs.

Cibus (NASDAQ: CBUS) has affirmed its collaboration with RTDC and Albaugh to commercialize its Clethodim-tolerant HT-3 rice trait, a gene-edited weed management solution for U.S. rice farmers. The partnership combines Cibus' gene editing expertise with Albaugh's crop protection and market development capabilities.

The company has secured four seed partners for this trait - two in the United States and two in South America - and is in discussions with major rice seed companies in Asia. The HT-3 trait represents a breakthrough in herbicide tolerance technology and is expected to be the first of several stacked weed management traits in rice from Cibus.

Cibus (Nasdaq: CBUS) and Biographica have announced a collaborative pilot project to advance disease resistance in oilseed rape and Canola. The partnership combines Biographica's proprietary AI and machine learning platform for gene target identification with Cibus' expertise in crop trait development. Biographica will analyze gene targets associated with disease resistance, while Cibus will focus on developing crop varieties with enhanced resilience. The collaboration aims to identify multiple modes of action for developing durable disease resistance in plants, potentially accelerating the delivery of improved crop varieties to farmers worldwide.

Cibus (Nasdaq: CBUS), an agricultural technology company specializing in plant trait development and licensing, has announced its participation in the 13th Annual Roth Technology Conference. The event will take place in New York City on November 19-20, 2024. Rory Riggs, Co-Founder, CEO, and Chairman, will represent the company at the conference. Attendees interested in meeting with Cibus representatives during either day of the conference are encouraged to arrange appointments through their conference host representative or directly with the company.

Cibus (NASDAQ: CBUS) has successfully completed gene edits in Canola for its 4th mode of action targeting Sclerotinia (White Mold) resistance trait, with greenhouse results expected in Q1 2025. This achievement follows positive field trial results from their 2nd mode of action, which demonstrated enhanced disease resistance. Sclerotinia is identified as the most significant disease affecting Canola yields and the second most impactful in Soybean. The company's approach involves developing multiple modes of action for durable disease resistance, with potential applications beyond Canola to other crops like Soybean.

Cibus reported its third quarter financial results and provided a year-to-date business update for 2024. The company announced a strategic realignment focusing on commercial opportunities, particularly in weed management for rice, pod shatter reduction in canola, and sclerotinia resistance in canola and soybean.

Key achievements include agreements with four major seed companies, successful field trials for HT3 in rice, and positive greenhouse results for HT2 in canola. The soybean platform is on track to be operational by the end of 2024. The company initiated actions to achieve $10 million in annualized cost savings, reducing monthly cash usage by 20%.

Financially, the company reported a net loss of $201.5 million for Q3 2024, primarily due to a $181.4 million goodwill impairment. Cash and cash equivalents were $28.8 million as of September 30, 2024. R&D expenses decreased to $13.0 million, and SG&A expenses decreased to $7.7 million.